These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 36542291

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.
    Pawlowska M, Bogiel M, Duda J, Sieradzki E.
    Eur J Clin Pharmacol; 2015 Jun; 71(6):699-705. PubMed ID: 25953735
    [Abstract] [Full Text] [Related]

  • 5. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.
    Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ.
    Arch Pharm Res; 2020 Nov; 43(11):1207-1213. PubMed ID: 33247397
    [Abstract] [Full Text] [Related]

  • 6. Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.
    Byeon JY, Kim YH, Na HS, Jang JH, Kim SH, Lee YJ, Bae JW, Kim IS, Jang CG, Chung MW, Lee SY.
    Arch Pharm Res; 2015 Nov; 38(11):2083-91. PubMed ID: 26254792
    [Abstract] [Full Text] [Related]

  • 7. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
    Dalmadi B, Leibinger J, Szeberényi S, Borbás T, Farkas S, Szombathelyi Z, Tihanyi K.
    Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
    Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ.
    Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects.
    Jung EH, Lee CM, Byeon JY, Shin HB, Oh KY, Cho CK, Lim CW, Jang CG, Lee SY, Lee YJ.
    Arch Pharm Res; 2020 Sep; 43(9):976-981. PubMed ID: 32661920
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.
    Ryu S, Park S, Lee JH, Kim YR, Na HS, Lim HS, Choi HY, Hwang IY, Lee JG, Park ZW, Oh WY, Kim JM, Choi SE.
    Clin Transl Sci; 2017 Mar; 10(2):93-101. PubMed ID: 28296334
    [Abstract] [Full Text] [Related]

  • 19. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.
    Guo L, Wang S, Wan Z, Ni S, Xu B, Zhao X, Liu L.
    J Clin Pharm Ther; 2020 Aug; 45(4):632-637. PubMed ID: 32379356
    [Abstract] [Full Text] [Related]

  • 20. Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.
    Chen B, Xu Y, Jiang T, Feng R, Sun J, Zhang W, Yang W, Li J, Adeniyi O, Chen H.
    J Clin Pharm Ther; 2013 Dec; 38(6):504-11. PubMed ID: 23981149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.